



## HealthTech For Care (HTFC) looks back on its first pitch competition during the HealthTech Innovation Days (HTID) on October 13 & 14, 2022 in Paris

*25 companies from 7 European countries from the Biotech, Medtech, Innovative Services & Digital Health sectors, selected by European clusters, presented their innovations to a jury composed of HTFC sponsors and the HTID health innovation ecosystem.*

**Paris, October 27, 2022,** During the 4<sup>th</sup> edition of the HTID, the first pitch competition of European companies in the healthcare sector, committed to patients, was a great success. All companies had the great opportunity to gain more visibility and to meet the European ecosystem for partnership and investment. The enthusiasm of sponsors and the high quality of companies selected by the European clusters, show that Europe is endowed with significant talents in which we must invest to improve access to innovative medical solutions for all patients..

During the closing ceremony, the "HealthTech For Care Innovation" prize was awarded to the top 3. Watch the award ceremony in replay: <https://www.youtube.com/watch?v=d2JL4qBnT7c&t=9s>

**1<sup>st</sup> place:** MRM Health is a Belgian biotech developing innovative microbiome-based biotherapeutics for inflammatory, CNS and metabolic diseases. Their disruptive CORAL<sup>®</sup> technology platform allows to design therapeutics based on specific combinations of 5 to 10 live gut bacteria and manufacture these combinations in a single standardized and effective single process. Their most advanced program MH002, a defined 6-strain live biotherapeutic, is currently tested in ongoing phase 2 trials for both Ulcerative Colitis and for the orphan disease indication Pouchitis.

*"As a young company acting in the novel microbiome field, enhancing exposure to the investment and pharma community is key. Participation to HTID and the pitch competition created direct value for MRM Health by being able to showcase both the microbiome field and our unique position therein. I recommend HTID to all companies that want to expose their project to big pharma, banks and investors and to have more visibility! Thanks again to the organizer for creating this opportunity and I already look forward for HTID5."* **Sam Possemiers, CEO, MRM Health**

**2<sup>nd</sup> place:** FluoSphera is developing the next generation of microphysiological systems (MPS) to revolutionize drug discovery. MPS are the most predictive tools to discover future therapies for patients needing them. The mission of FluoSphera is to democratize MPS in the pharmaceutical industry to stop missing the most promising drugs for patients while reducing animal experimentation.

*"The pitch session was a very good experience to highlight how our innovation will change the life of patients. It was also an excellent opportunity to network with the impressive companies pitching there, as well as with strategic people among the attendees and jury members."* **Gregory Segala, CEO and Co-Founder, FluoSphera**

**3<sup>rd</sup> place:** ViDAC Pharma is a pre-IPO clinical stage biopharmaceutical company developing first-in-class anti-cancer drugs by modifying the hyper glycolytic (Warburg Effect) Tumor Microenvironment. The

Company developed a new paradigm in Drug Discovery: The Toposteric Effect, displacing active proteins from their wrong anchor without affecting their activity.

*“We participated in the 4th edition of HealthTech Innovation Days, on October 13&14 2022 and were selected as one of the 25 companies to give a Pitch and were one of the three companies to receive the Prize for Innovation in this remarkably well-organized Healthcare convention. Our participation to the contest and our being distinguished by a Prize already gave us access to more contacts and sponsors and we are now in active discussions with some of them.”* **Max Herzberg, CEO Vidac Pharma**

We thank all the companies that participated in this first session: [A4Cell](#), [Abscint](#), [AbolerIS Pharma](#), [ANeuroTech](#), [Aptus](#), [Bloomlife](#), [Clouds of Care](#), [E-scopics](#), [FluoSphera](#), [Iomed](#), [Lattice Medical](#), [mimiX biotherapeutics](#), [Neomatrix](#), [Neuropath](#), [Predilife](#), [Pulsify Medical](#), [Radiomics](#), [Regen Lab](#), [Smart immune](#), [Transactiva](#), [Vidac Pharma Ltd.](#), [Leucid Bio](#), [miDiagnostics](#), [MRM Health](#) & [Yoni Solutions](#).

We also would like to thank our sponsors that were involved as a jury for this first edition of pitch sessions: [Agile Capital Markets](#), [Amgen France](#), [BNP Paribas](#), [Bpifrance](#), [Bristol Myers Squibb](#), [Cenpots](#), [Cepton Strategies/Vintura](#), [Dechert](#), [EIT Health](#), [Euronext](#), [Ferring](#), [Jeito Capital](#), [Icosa](#), [Invest Securities](#), [Ipsen](#), [Leem](#) (Les Entreprises du Médicament), [Life Sciences Acceleration Alliance](#), [McDermott Will & Emery](#), [Organon](#), [Pharma Intelligence](#), [Rothschild&Co](#), [Sanofi](#), [Servier](#), [Sofinnova Partners](#), [Stifel](#) et [Alpha Blue Ocean](#)

We would also like to thank our clusters that helped us select our 25 candidates: **Atlanpole biotherapies**, **Asebio**, **BioAlps**, **BIO Deutschland**, **BioIndustry Association**, **BioValley France**, **BioWin**, **CEBR**, **EuroBioMed**, **Federchimica Assobiotec**, **flanders.bio**, **HollandBIO**, **IREFI**, **LyonBioPole**, **Medicen**, **Medvia**, **NSL clubster** and **Swiss Biotech**.

### **About HealthTech For Care**

The HealthTech For Care endowment fund is designed to support and promote access to healthcare for all, and more specifically to new medical technologies and medicines. The missions of the endowment fund are organized around three main areas: to support the development of the entire healthcare ecosystem, to accelerate the development of innovative therapies and medicines, and to promote better access for patients to the healthcare system in France and Europe. The governance of HealthTech For Care includes Maryvonne Hiance, Elsy Boglioli, David Caumartin, Pierre Courteille, Marc Dechamps, Eric Falcand, Frédéric Girard, Marc Julien, Anaïs Le Corvec, Cédric Moreau, Christian Pierret and Christian Policard.

<https://www.linkedin.com/company/healthtech-for-care/>

<https://htfc-eu.com>

### **About HealthTech Innovation Days**

The HealthTech Innovation Days (HTID®) event, initiated by France Biotech, provides a platform for promising European life science companies to accelerate their growth and bring innovation to patients. Each year, this European event brings together more than 800 participants, including 300 global investors, more than 165 innovative European healthcare companies and some 15 pharmaceutical groups. The 4th edition took place on October 13 and 14, 2022 in a hybrid format, combining in-person presentations, panels and one-on-one meetings in Paris with a virtual platform. It is organized by the HealthTech For Care endowment fund. The HealthTech Innovation Days are sponsored by international pharmaceutical companies, other health innovation companies, investors and many international opinion leaders. <https://htfc-eu.com/htid/>

### **About the BioAlps Association**

Founded in 2003, the BioAlps Association is supported by the cantons of Bern, Fribourg, Geneva, Jura, Neuchâtel, Valais and Vaud, by the State Secretariat for Economic Affairs (SECO) and by 14 academic institutions in the region. The association represents the life sciences community of Western Switzerland and supports it through the organisation of numerous events in Switzerland and internationally, as well as through regular publications. BioAlps thus offers representatives from the academic world and the industrial, financial, political and media sectors opportunities for synergies within the life sciences ecosystem.

### **About flanders.bio**

flanders.bio is a dynamic, member driven organisation with currently more than 340 members from Belgium and abroad. Its membership base includes biotech start-ups and scale-ups, R&D focused biopharma and agrifood-tech companies, next to research institutes and a diverse community of specialist competence providers and investors. flanders.bio helps its members to create value by organising networking and training activities, supporting internationalisation, providing communication and info services and building expertise. With its exceptional density of R&D and clinical development actors, and a proven track record of companies bringing biotech research to market, flanders.bio and its members are proud advocates of a reputable and growing global impact ecosystem in life sciences in Europe. Get to know the regional ecosystem on June 1st, 2023 at Knowledge for Growth.

### **Press contacts**

#### **Relations presse**

Margaux Puech

[mpuech@ulyse-communication.com](mailto:mpuech@ulyse-communication.com)

+33(0)7 86 16 01 09

#### **Relations presse**

Pierre-Louis Germain

[plgermain@ulyse-communication.com](mailto:plgermain@ulyse-communication.com)

+33(0)6 64 79 97 51

#### **HTFC**

Nathalie Donne

[nathalie.donne@insead.eu](mailto:nathalie.donne@insead.eu)

+33(0)6 67 67 44 97

#### **HTFC**

Solène Goupy

[solene.goupy@htfc-eu.com](mailto:solene.goupy@htfc-eu.com)

+33(0)6 38 03 80 19